CPS1及其LncRNA在胆管细胞癌诊治中的研究进展

摘要/Abstract

摘要： 胆管细胞癌(Intrahepatic Cholangiocarcinoma,ICC)是胆管上皮的一种恶性肿瘤。目前,胆管癌的诊断通常发生在疾病进展或扩散阶段,从而导致患者的预后非常差。临床上缺乏可用于诊断ICC的生物标志物。随着基因检测技术的成熟和人类基因谱的不断充实,越来越多的肿瘤相关基因引起我们重视。本文对氨甲酰磷酸酯(CPS1)以及其同源长链非编码RNA在ICC诊断中的作用及研究价值作一综述。

关键词: 肝内胆管细胞癌, CPS1, CPS1-IT1, 生物标志物

阿卜来海提, 马森林, 陈明泉. CPS1及其LncRNA在胆管细胞癌诊治中的研究进展[J]. 肝脏, 2022, 27(3): 373-375.

参考文献

[1] Squadroni M, Tondulli L, Gatta G, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol,2017,116:11-31.
[2] Le Faouder J, Gigante E, Léger T, et al. Proteomic landscape of cholangiocarcinomas reveals three different subgroups according to their localization and the aspect of non-tumor liver. Proteomics Clin Appl,2019,13:e1800128.
[3] Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology,2011,54:173-184.
[4] Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int,2019,39 Suppl 1:143-155.
[5] Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet,2012,44:690-693.
[6] Talabnin K, Talabnin C, Khiaowichit J, et al. High expression of tissue O-linked glycans is associated with a malignant phenotype of cholangiocarcinoma. J Int Med Res,2021,49:300060520976864.
[7] Talabnin K, Talabnin C, Kumagai T, et al. Ganglioside GM2: a potential biomarker for cholangiocarcinoma. J Int Med Res,2020,48:300060520903216.
[8] Tsujie M, Iwai T, Kubo S, et al. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Jpn J Clin Oncol. 2021,51:911-917.
[9] Gong X, Zou L, Wang M, et al. Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. Artif Cells Nanomed Biotechnol,2020,48:53-59.
[10] Pierson DL, Brien JM. Human carbamylphosphate synthetase I. Stabilization, purification, and partial characterization of the enzyme from human liver. J Biol Chem, 1980,255:7891-7895.
[11] Huang X, Raushel FM. Restricted passage of reaction intermediates through the ammonia tunnel of carbamoyl phosphate synthetase. J Biol Chem,2000,275:26233-26240.
[12] Häberle J, Schmidt E, Pauli S, et al. Gene structure of human carbamylphosphate synthetase 1 and novel mutations in patients with neonatal onset. Hum Mutat, 2003,21:444.
[13] Moreno-Morcillo M, Grande-García A, et al. Structural Insight into the Core of CAD, the Multifunctional Protein Leading De Novo Pyrimidine Biosynthesis. Structure,2017,25:912-923.
[14] Zhang W, Dong Z, Xu M, et al. SWI/SNF complex subunit BAF60a represses hepatic ureagenesis through a crosstalk between YB-1 and PGC-1α. Mol Metab, 2020,32:85-96.
[15] Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab,2013,110:179-180.
[16] Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest,2008,88:78-88.
[17] Liu TH, Li DC, Gu CF, et al. Carbamyl phosphate synthetase I. A novel marker for gastric carcinoma. Chin Med J (Engl),1989,102:630-638.
[18] Çeliktas M, Tanaka I, Tripathi SC, et al. Role of CPS1 in cell growth, metabolism and prognosis in LKB1-inactivated lung adenocarcinoma. J Natl Cancer Inst,2017,109:1-9.
[19] Cardona DM, Zhang X, Liu C. Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. Am J Clin Pathol,2009,132:877-882.
[20] Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest,2008,88:78-88.
[21] Kim J, Hu Z, Cai L, et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature,2017,546:168-172.
[22] Liu X, Zhang X, et al. Caspase recruitment domain family member 10 regulates carbamoyl phosphate synthase 1 and promotes cancer growth in bladder cancer cells. J Cell Mol Med,2019,23:8128-8138.
[23] Rolfe A, Yao S, Nguyen TV, et al. Discovery of 2,6-dimethylpiperazines as allosteric Inhibitors of CPS1. ACS Med Chem Lett,2020,11:1305-1309.
[24] Wang TH, Yu CC, Lin YS, et al. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition. Oncotarget,2016,7:43588-43603.
[25] Wang YS, Ma LN, et al. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis. Eur Rev Med Pharmacol Sci, 2017,21:3169-3175.
[26] Xiaoguang Z, Meirong L, et al. Long noncoding RNA CPS1-IT1 suppresses cell proliferation and metastasis in human lung cancer. Oncol Res,2017,25:373-380.
[27] Zhang W, Yuan W, et al. LncRNA CPS1-IT1 suppresses EMT and metastasis of colorectal cancer by inhibiting hypoxia-induced autophagy through inactivation of HIF-1α. Biochimie,2018,144:21-27.
[28] Zhou X, Rao Y, Sun Q, et al. Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1. J Cell Physiol,2019,234:22017-22027.
[29] Ma SL, Li AJ, Hu ZY, et al. Coexpression of the carbamoylphosphate synthase 1 gene and its long noncoding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma. Mol Med Rep,2015,12:7915-7926.
[30] Shi J, Li X, Zhang F, et al. The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma. Cell Physiol Biochem,2018,49:1694-1702.